COMPASS Pathways plc Stock Research

Market Summary

USD8.68+0.46

Delayed

5.60%

CMPS Stock Price

CMPS RSI Chart

CMPS Valuation

Market Cap

369.1M

Price/Earnings (Trailing)

-4.03

EV/EBITDA

-2.49

Price/Free Cashflow

-3.48

MarketCap/EBT

-4.05

CMPS Price/Earnings (Trailing)

CMPS Profitability

Return on Equity

-50.48%

Return on Assets

-46.38%

Free Cashflow Yield

-28.73%

CMPS Fundamentals

CMPS Earnings

Earnings (TTM)

-91.5M

Earnings Y/Y

-20.57%

Earnings Q/Q

-68.34%

Price Action

52 Week Range

6.9721.50

(Low)(High)

Last 7 days

1.1%

Last 30 days

-13.1%

Last 90 days

-15.7%

CMPS Financial Health

Current Ratio

12.29

CMPS Investor Care

Shares Dilution (1Y)

1.96%

Diluted EPS (TTM)

-2.16

Financials for COMPASS Pathways

Income Statement (Last 12 Months)
Description	(%) Q/Q

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-12.1%	197	225	239	272	301
Current Assets	-12.3%	192	218	232	267	295
Cash Equivalents	-17.3%	143	173	207	244	273
Net PPE	11.2%	1.00	1.00	1.00	0.00	0.00
Liabilities	-46.5%	16.00	30.00	14.00	13.00	16.00
Current Liabilities	-47.2%	16.00	30.00	13.00	12.00	15.00
Shareholder's Equity	-6.8%	181	195	225	260	284
Retained Earnings	-13.4%	-261	-230	-211	-190	-169
Additional Paid-In Capital	0.9%	459	455	451	448	445
Shares Outstanding	0.1%	43.00	42.00	42.00	-	-

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-27.8%	-105,451	-82,518	-77,392	-77,090	-67,745
Share Based Compensation	4.2%	13,123	12,592	11,375	10,101	8,639
Cashflow From Investing	-2.4%	-596	-582	-673	-346	-334
Cashflow From Financing	-13.8%	1,040	1,206	1,256	155,877	156,646

Risks for CMPS

What is the probability of a big loss on CMPS?

91.2%

Probability that COMPASS Pathways stock will be more than 20% underwater in next one year

61.8%

Probability that COMPASS Pathways stock will be more than 30% underwater in next one year.

55.9%

Probability that COMPASS Pathways stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CMPS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if COMPASS Pathways was unfortunately bought at previous high price.

Drawdowns

Returns for CMPS

Cumulative Returns on CMPS

Which funds bought or sold CMPS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-06	Rockefeller Capital Management L.P.	unchanged	-	-44,000	131,000	-%
2023-02-24	SRS Capital Advisors, Inc.	new	-	281	281	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	unchanged	-	241	241	-%
2023-02-15	Steward Partners Investment Advisory, LLC	unchanged	-	-2,970	8,030	-%
2023-02-15	HOWE & RUSLING INC	sold off	-100	-	-	-%
2023-02-15	PFS INVESTMENTS INC.	added	14.43	-76,000	456,000	0.01%
2023-02-15	Virtu Financial LLC	sold off	-100	-108,000	-	-%
2023-02-15	JANE STREET GROUP, LLC	sold off	-100	-437,000	-	-%
2023-02-15	Front Row Advisors LLC	unchanged	-	-1,000	1,000	-%
2023-02-14	CITADEL ADVISORS LLC	added	20.68	-151,997	1,414,000	-%

Latest Funds Activity

Are funds buying CMPS calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own CMPS

No. of Funds

COMPASS Pathways News

Schedule 13G FIlings of COMPASS Pathways

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	compass pathways plc	10.2%	4,354,395	SC 13G/A

CMPS Fair Value

Recent SEC filings of COMPASS Pathways

View All Filings

Date Filed	Form Type	Document
Feb 28, 2023	10-K	Annual Report
Feb 28, 2023	8-K	Current Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 03, 2023	4	Insider Trading
Feb 03, 2023	4	Insider Trading
Feb 03, 2023	4	Insider Trading
Feb 03, 2023	4	Insider Trading
Feb 03, 2023	4	Insider Trading
Feb 03, 2023	4	Insider Trading
Jan 20, 2023	S-8	Employee Benefits Plan

Latest Insider Trading transactions for CMPS

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-02	Nath Kabir	acquired	-	-	25,200	chief executive officer
2023-02-02	Malievskaia Ekaterina	acquired	-	-	11,700	chief innovation officer
2023-02-02	OWENS MATTHEW A	acquired	-	-	10,800	general counsel & clo
2023-02-02	FALVEY MICHAEL	acquired	-	-	22,500	chief financial officer
2023-02-02	Goldsmith George Jay	acquired	-	-	11,700	-
2023-02-01	Goldsmith George Jay	sold (taxes)	-56,052	10.61	-5,283	-
2023-02-01	Goldsmith George Jay	sold (taxes)	-35,023	10.61	-3,301	-
2023-02-01	Malievskaia Ekaterina	sold (taxes)	-35,023	10.61	-3,301	chief innovation officer
2023-02-01	Malievskaia Ekaterina	sold (taxes)	-56,052	10.61	-5,283	chief innovation officer
2023-02-01	OWENS MATTHEW A	sold (taxes)	-17,962	10.61	-1,693	general counsel & clo

About COMPASS Pathways

George J. Goldsmith

www.compasspathways.com

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CMPS Income Statement

2022-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
OPERATING EXPENSES:
Research and development	$ 65,053	$ 44,027	$ 23,366
General and administrative	45,350	39,194	28,027
Total operating expenses	110,403	83,221	51,393
LOSS FROM OPERATIONS:	(110,403)	(83,221)	(51,393)
OTHER INCOME (EXPENSE), NET:
Other income, net	4,061	40	319
Foreign exchange gains (losses)	821	1,990	(11,702)
Fair value change of convertible notes	0	0	(1,041)
Fair value change of convertible notes - due to a related party	0	0	(730)
Benefit from R&D tax credit	14,424	9,648	4,245
Total other income (expense), net	19,306	11,678	(8,909)
Loss before income taxes	(91,097)	(71,543)	(60,302)
Income tax expense	(408)	(199)	(32)
Net loss	(91,505)	(71,742)	(60,334)
Other comprehensive loss:
Foreign exchange translation adjustment	(25,707)	(5,745)	14,683
Comprehensive loss	$ (117,212)	$ (77,487)	$ (45,651)
Net loss per share attributable to ordinary shareholders - basic (in dollars per share)	$ (2.16)	$ (1.79)	$ (3.55)
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)	$ (2.16)	$ (1.79)	$ (3.55)
Weighted average ordinary shares outstanding - basic (in shares)	42,436,292	39,997,587	16,991,664
Weighted average ordinary shares outstanding - diluted (in shares)	42,436,292	39,997,587	16,991,664

CMPS Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 143,206	$ 273,243
Restricted cash	175	104
Prepaid income tax	575	332
Prepaid expenses and other current assets	47,695	21,621
Total current assets	191,651	295,300
NON-CURRENT ASSETS:
Investment	469	525
Property and equipment, net	617	398
Operating lease right-of-use assets	2,006	3,696
Deferred tax assets	2,224	766
Other assets	327	213
Total assets	197,294	300,898
CURRENT LIABILITIES:
Accounts payable	4,761	2,564
Accrued expenses and other liabilities	9,325	10,308
Operating lease liabilities - current	1,510	2,235
Total current liabilities	15,596	15,107
NON-CURRENT LIABILITIES
Operating lease liabilities - non-current	418	1,379
Total liabilities	16,014	16,486
Commitments and contingencies (Note 15)
SHAREHOLDERS' EQUITY:
Additional paid-in capital	458,825	444,750
Accumulated other comprehensive (loss)/income	(16,867)	8,840
Accumulated deficit	(261,146)	(169,641)
Total shareholders' equity	181,280	284,412
Total liabilities and shareholders' equity	197,294	300,898
Ordinary shares
SHAREHOLDERS' EQUITY:
Ordinary and deferred shares	440	435
Deferred Shares
SHAREHOLDERS' EQUITY:
Ordinary and deferred shares	$ 28	$ 28